Flamingo Therapeutics is a newly created, early stage spin-off company from institutions in Belgium and the US, which has recently secured substantial funding from venture capital investors to develop novel treatment options for various cancers, focusing on long non-coding RNA...
Read More »Researchers identify targeting of the lncRNA SAF as a potential means to specifically induce cell death in HIV-1-infected macrophages
Long noncoding RNAs (lncRNAs) impart significant regulatory functions in a diverse array of biological pathways and manipulation of these RNAs provides an important avenue to modulate such pathways, particularly in disease. Our knowledge about lncRNAs' role...
Read More »Exosome-transferred lncRNAs at the core of cancer bone lesions
Exosome-mediated transfer of regulatory RNAs is a key feature that enables cancer cells to shape a tumor-promoting environment. Cancers growing in the bone can use this communication modality to...
Read More »Profiling Therapeutically Actionable Long Non-coding RNAs Using CRISPR-Cas9 Screening
Long non-coding RNAs (lncRNAs) represent a huge reservoir of potential cancer targets. Such "onco-lncRNAs" have resisted traditional RNAi methods, but CRISPR-Cas9 genome editing now promises functional screens at high throughput and low cost....
Read More »A lncRNA-mediated regulatory layer safeguarding embryonic cell fate transitions
Human protein-coding genes are often accompanied by divergently transcribed non-coding RNAs whose functions, especially in cell fate decisions, are...
Read More »lncRNA Paupar is needed for brain development
Scientists have identified a non-coding RNA, called Paupar, influences how healthy brains develop during early life. They have shown that Paupar orchestrates proteins that control neurodevelopment...
Read More »Rare splice variants in long non-coding RNAs
Long non-coding RNAs (lncRNAs) form a substantial component of the transcriptome and are involved in a wide variety of regulatory mechanisms. Compared to protein-coding genes, they are often expressed at low levels and are restricted to a narrow range of cell types or developmental stages. As a consequence, the diversity of their isoforms is still far from being recorded and ...
Read More »Expression levels of long non-coding RNAs are prognostic for AML outcome
Long non-coding RNA (lncRNA) expression has been implicated in a range of molecular mechanisms that are central in cancer. However, lncRNA expression...
Read More »Pan-Cancer Analysis of lncRNA regulation supports their targeting of cancer genes in each tumor context
Long noncoding RNAs (lncRNAs) are commonly dysregulated in tumors, but only a handful are known to play pathophysiological roles in cancer. A team led by researchers at Baylor College of...
Read More »The decade of exosomal long RNA species
Exosomes have emerged as a novel approach for the treatment and diagnosis of cancer after RNA content was discovered in exosomes in 2007. As important meditators of intercellular communication, exosomes have become a strong focus of investigation for researchers in the past decade, as witnessed through the exponential increase of research on exosomes. The capability of exosomes to transfer functionally ...
Read More »